Phase II study of the multitargeted antifolate LY231514 (ALIMTA™, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer
Open Access
- 1 January 2000
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 11 (1) , 101-104
- https://doi.org/10.1023/a:1008305205159
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Clinical studies with MTABritish Journal of Cancer, 1998
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992
- A dideazatetrahydrofolate analog lacking a chiral center at C-6: N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5yl)ethyl[benzoyl]-L-glutamic acid is an inhibitor of thymidylate synthaseJournal of Medicinal Chemistry, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958